The Zhitong Finance App learned that recently, Changfeng Pharmaceutical (02652.HK) announced that its first-in-class (first-in-class) phase I clinical trial of ICF004 (chemical drug class 1) for the treatment of interstitial lung disease (ILD) has successfully completed the enrollment and administration of the first healthy volunteer. The project is a scientific research result developed by Changfeng Pharmaceutical in collaboration with Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine. The drug candidate has officially entered a new stage of clinical trial in humans.

The Zhitong Finance App learned that recently, Changfeng Pharmaceutical (02652.HK) announced that its first-in-class (first-in-class) phase I clinical trial of ICF004 (chemical drug class 1) for the treatment of interstitial lung disease (ILD) has successfully completed the enrollment and administration of the first healthy volunteer. The project is a scientific research result developed by Changfeng Pharmaceutical in collaboration with Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine. The drug candidate has officially entered a new stage of clinical trial in humans.